Aurobindo Pharma FY24 Annual Earnings Summary

FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.

Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.

While pricing has stabilized recently, any reversal could pressure US margins and revenue growth.

As a late entrant, Aurobindo's Revlimid volume share is expected to be lower than early entrants, limiting upside.

Management acknowledged that full ramp-up of Pen-G capacity may take time, with clarity only expected by February 2024.

While current price erosion is neutral, increased competition could pressure margins in oral solids and injectables.

Pen-G, China, and biosimilar plants face commissioning delays; revenue contribution may shift to FY26.

Analyst questioned if 20% margin guidance includes gRevlimid; management confirmed, but any volume/pricing shortfall could miss target.

Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.

Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.

Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.

Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.